Trial
NCT01925118
Irradiated Donor Lymphocyte Infusion Plus High-dose IL-2
Phase IITERMINATEDEFFICACY/FUTILITYConfidence: MEDIUM
Sponsor
Seoul National University Hospital
Collaborators
—
Condition
Metastatic Malignant Melanoma and Renal Cell Carcinoma
Intervention
Irradiated donor lymphocyte infusion
Why stopped
Ineffectiveness
Provenance
Dataset: 2026-07-02 • Source: ClinicalTrials.gov API v2 • Last update: 2016-04-26